Abstract
Colon cancer is the third most commonly diagnosed cancer and the second leading cause of cancer death in both men and women in the U.S. The exact cause of the colonic cancer is still unknown but has several risk factors like the age, the colonic polyps, the genetic alterations and others. The aim of this review is to put a light on the pathophysiology of the colonic cancer like the genomic and chromosomal instabilities and oncogens mutations like the EGFR ; and focus on the immunotherapies available for treating it including the FDA approved agents like Cetuximab, Bevacizumab, Regorafenib , and other drugs that are still under clinical trial.